Wire Stories

TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)

Patients underwent BNCT using TAE Life Sciences� Neutron Beam System as part of Neuboron Medical Group�s NeuPex System at Xiamen…

3 years ago

TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)

Patients underwent BNCT using TAE Life Sciences� Neutron Beam System as part of Neuboron Medical Group�s NeuPex System at Xiamen…

3 years ago

Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts

Company Funded Through Results of U.S. Early Feasibility Study of DurAVR� BRISBANE, Australia and EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Ltd (ASX:…

3 years ago

Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts

Company Funded Through Results of U.S. Early Feasibility Study of DurAVR� BRISBANE, Australia and EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Ltd (ASX:…

3 years ago

Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts

Company Funded Through Results of U.S. Early Feasibility Study of DurAVR� BRISBANE, Australia and EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Ltd (ASX:…

3 years ago

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and…

3 years ago

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and…

3 years ago

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and…

3 years ago

NEW YORK & D�SSELDORF, Germany & TOKYO--(BUSINESS WIRE)--#asahikasei--Asahi Kasei, a diversified Japanese multinational company, has completed the construction of its…

3 years ago

NEW YORK & D�SSELDORF, Germany & TOKYO--(BUSINESS WIRE)--#asahikasei--Asahi Kasei, a diversified Japanese multinational company, has completed the construction of its…

3 years ago
Show more Posts
Show previous Posts